Table 2.
Variable |
PVC Grp 1 (n=599) |
PVC Grp 2 (n=82) |
PVC Grp 3 (n=81) |
PVC Grp 4 (n=83) |
P value |
Demographics | |||||
Males | 516 (86%)† | 75 (93%) | 75 (90%) | 79 (96%)* | 0.02 |
Hypertension | 428 (71%) | 62 (76%) | 61 (73%) | 56 (68%) | 0.66 |
Diabetes | 185 (31%) | 32 (39%) | 27(32%) | 29 (35%) | 0.41 |
CAD | 155 (26%) | 22 (27%) | 30 (36%) | 28 (34%) | 0.12 |
Ambulatory ECG | |||||
Heart rate (bpm) | 75±11 | 72±11 | 72±10 | 74±10 | 0.08 |
PAC burden (%) | 1.6±2.4 | 2.5±3.6‡ | 2.3±3.6 | 1.4±1.2† | 0.03 |
AF burden (%) | 1.2±6.6 | 1.4±7.8 | 1.1±6 | 0.1±0.7 | 0.55 |
SVT episodes (No.) | 138±1416 | 331±1869 | 279±2071 | 18±62 | 0.03 |
Total PVC (No.) | 702±2191 | 20799±9182 | 48394±20367 | 252199±41943 | 0.000 |
VT episodes (No.) | 0.43±5.9‡ | 0.49±1.4‡ | 0.69±1.3‡ | 20±74*†~ | 0.000 |
Echocardiographic parameters | (n=296) | (n=49) | (n=48) | (n=40) | P value |
LVEF (%) | 52.7±9.4 | 50.2±9.8 | 47.1±13.5* | 44.9±13.9* | 0.0001 |
LVEF < 50% | 53 (18%)~‡ | 14 (29%) | 18 (37%)* | 17 (42%)* | 0.0001 |
LVEDD (cm) | 4.8±1.3 | 5.0±0.8 | 5.0±0.8 | 5.3±0.7* | 0.03 |
LVESD (cm) | 3.3±0.7†~‡ | 3.7±0.9* | 3.8±0.9* | 4.1±0.9* | 0.000 |
LA (cm) | 3.8±0.61† | 4.1±0.6* | 3.9±0.7 | 4.1±0.70 | 0.008 |
PVC group 1 (< 1%, median (IQR)-0.9 (0.9-0.9), n 600), PVC group 2 (range: 1.1-2.4%, median (IQR)-1.4 (1.1-2.0), n=81), PVC group 3 (range: 2.5-5.8%, median (IQR)-4.1 (3.3-4.9), n=83), PVC group 4 (range: 5.9-44.7%, median (IQR)-14.1 (8.8-19.9), n=82). Data is presented as mean and SD. Note that echocardiographic data includes a lower number of patients since not all had associated 2-D echocardiogram. P value using one-way ANOVA. Significant Bonferroni correction (<0.05) for PVC
group 1
group 2
group 3
and group 4.
Grp-Group, LVEF-Left ventricular ejection fraction, LVESD-Left ventricular end systolic diameter, PAC-premature atrial contraction, PVC-Premature ventricular contraction, SVT-Supraventricular tachycardia, VT-Ventricular tachycardia.